SynthesisIntegrative cancer therapies
Efficacy of Herbal Medicine Therapy Combined With Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis.
Synthesis in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Acupuncture and Moxibustion for Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Standard Treatment: A Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- Cancer cachexia as an immunometabolic syndrome: targeting the immunometabolic interface with traditional Chinese Medicine monomers and formulas.Frontiers in immunology · 2026Review
- Comment on 'Efficacy of Herbal Medicine Therapy Combined With Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis'.Integrative cancer therapiesArticle
- Response to Letter Regarding "Herbal Medicine Combined With Chemotherapy in Advanced NSCLC".Integrative cancer therapiesArticle
- The Definition Dilemma of Fuzheng-Based Therapy in NSCLC Systematic Reviews and a Proposal for a Dual-Anchor Model.Integrative cancer therapiesArticle
- Comments on "Efficacy of Herbal Medicine Therapy Combined with Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis".Integrative cancer therapiesArticle
- Response to the Letter to the Editor Regarding "Efficacy of Herbal Medicine Therapy Combined with Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis".Integrative cancer therapiesArticle
- Combination Therapy ofIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer, a leading cause of mortality, is often complicated by severe treatment-related side effects. Traditional herbal medicine (THM), particularly Fuzheng-Based Qi and Yin Therapy (FBQYT), has emerged as a promising adjuvant therapy to mitigate these effects and enhance immune response. This meta-analysis evaluates the efficacy and safety of THM as an adjunct to palliative chemotherapy.
methodsA systematic search was conducted in PubMed, EMBASE, ScienceON, RISS, KMBASE, OASIS, Cochrane Library, KISS, CNKI, and CiNii up to April 2025. Outcomes included tumor response, quality of life (QoL), adverse drug reactions (ADRs), and tumor markers. Eighty randomized controlled trials (RCTs) involving stage III/IV lung cancer patients were analyzed using Review Manager Software 5.4.1.
resultsCombining chemotherapy with THM significantly improved the objective response rate (ORR, RR 1.41) and disease control rate (DCR, RR 1.20). It also enhanced quality of life, increasing Karnofsky Performance Status (KPS) score (MD 8.53) and KPS improvement (RR 1.51), alongside improvements in Quality of Life Questionnaire-Core 30 (QLQ-C30) total score (MD 13.05). Tumor markers and most ADRs were reduced, except for neutropenia, liver injury, and diarrhea (
conclusionIntegrating THM with palliative chemotherapy enhances tumor response, QoL, and survival rates while reducing adverse effects. Further rigorous RCTs are needed to confirm these findings and address methodological limitations. REGISTRATION: PROSPERO CRD 42024523418.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.